Performances
| 1h | 24h | 7d | 30d | 60d | 90d |
|---|---|---|---|---|---|
| 0.19% | 1.00% | 19.23% | 12.13% | 37.39% | 42.84% |
Comparison
Fundraising not disclosed
Token not listed
Token not listed
Tokenomics
Top Holders
Open Markets
| # | Exchange | Pair | Price | +2% depth | -2% depth | Volume (24h) | volume % |
|---|
Follow Updates
Follow Lists
People
About BIO Protocol
BIO Protocol is a financial layer for decentralized science (DeSci), providing an open market for funding and trading tokenized biomedical research. Its core business revolves around BioDAOs—community-governed vehicles that pool capital to support early-stage projects. Users stake BIO tokens to gain voting rights and access to project token allocations, aligning incentives between researchers and communities.
The main pain point it addresses is the inefficiency of traditional biotech funding, which is often concentrated in a few institutions, opaque, and slow. BIO Protocol democratizes access by allowing anyone to participate in funding decisions and benefit from scientific breakthroughs.
In the past six months (March–September 2026), BIO Protocol has advanced its AI agent ecosystem. It launched BioAgents, an AI-driven framework for automating scientific tasks, and introduced Gaia, a comprehensive AI assistant for DeSci operations. The first BioAgent, AUBRAI, successfully completed its launch, generating over $100K in trading fees and attracting significant community participation. BIO staking has grown, with over 160M tokens staked, and the protocol launched a new Bio Markets page for real-time trading and analytics of ecosystem assets. BioXP, a loyalty points system, was also upgraded to reward quality contributions. Challenges remain, including regulatory uncertainty and the need to prove long-term scientific impact, but the protocol continues to expand its infrastructure for open science.
Bio Protocol completed a $6.9 million seed round led by Arthur Hayes. It later listed on Upbit supporting KRW/BTC/USDT pairs. OpenLabs launched to back scientific projects and agent collaboration via USDC revenue. Bio V2 will introduce IP tokens sold through Ignition Sales; first BioAgent project Aubrai was oversubscribed 14.6x. The protocol generated over $4 million in liquidity fees and is preparing DeFi integrations.
BIO Protocol team includes:
Paul Kohlhaas (Founder & CEO): Also founder of Molecule and VitaDAO, ex-ConsenSys, led Swiss government blockchain projects.
Clemens Ortlepp (Co-Founder & CPO): Founder of MTX Studio, focuses on decentralized tech and user-facing products.
James Sinka (Co-Founder, Science Lead): Oversees R&D and community engagement.
Tyler Golato (Co-Initiator): Contributes to scientific coordination.
Jose Pinto (Legal Counsel): Handles compliance and regulatory matters.